Synthetic Biologics, Inc. $SYN, a late-stage clinical company developing therapeutics focused on the gut microbiome, announced FYQ3 results. For the financial period ended September 30, 2016, EPS was -$0.09, beating the guidance by $0.01. During the period, general and administrative expenses rose to $2.1 million from $1.6 million, Y-o-Y. The rise is mainly the result of increase stock-based compensation, investor relations expenses and employee salaries, and benefit costs.